key: cord-0896992-ahvzxfnd
authors: Tea, F.; Ospina Stella, A.; Aggarwal, A.; Darley, D. R.; Pilli, D.; Vitale, D.; Merheb, V.; Lee, F. X. Z.; Cunningham, P.; Walker, G. J.; Brown, D. A.; Rawlinson, W. D.; Isaacs, S. R.; Mathivanan, V.; Hoffman, M.; Poehlmann, S.; Dwyer, D. E.; Rockett, R.; Sintchenko, V.; Hoad, V. C.; Irving, D. O.; Dore, G. J.; Gosbell, I. B.; Kelleher, A. D.; Matthews, G. V.; Brilot, F.; Turville, S. G.
title: SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants
date: 2020-12-22
journal: nan
DOI: 10.1101/2020.12.19.20248567
sha: d6627ee3446c977c12d8456bdbaa2cc2aa0b30ea
doc_id: 896992
cord_uid: ahvzxfnd

The SARS-CoV-2 antibody neutralization response and its evasion by emerging viral variants are unknown. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 RT-PCR-confirmed COVID-19 individuals with detailed demographics and followed up to seven months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization were associated with COVID-19 severity. A subgroup of high responders maintained high neutralizing responses over time, representing ideal convalescent plasma therapy donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal plasma donors and vaccine monitoring and design.

Control of the SARS-CoV-2 pandemic relies on population resistance to infection due to a 80 post-infection and vaccination-induced immunity. Current questions relate to the level, 81 breadth, and longevity of generated immunity, and whether mutation of the virus will 82 compromise immunity. Previous studies reported varying results in longitudinal changes of 83 the virus-specific antibody response. Some detected stable antibody titers 4-6 months after 84 diagnosis (1, 2), while others reported waning of the antibody response 2-3 months after 85 infection (3, 4). Differences in assay sensitivity and antigen targets may account for these 86 discrepancies, with Spike and nucleocapsid being the main antigens investigated. 87

Immunoreactivity to other abundant antigens, such as Membrane or Envelope, are unknown. 88

Neutralization of SARS-CoV-2 has been reported for antibodies that bind to Spike, a large 89 homo-trimeric glycoprotein studded across the viral surface (5, 6), whereas Membrane and 90

Envelope proteins, although exposed on the viral surface, remain to be identified as 91 neutralizing antibody targets. Rapid development of neutralizing antibody response to Spike 92 correlates with viral immunity, and individuals who seroconvert may develop a lasting 93 neutralization response (7). 94

The SARS-CoV-2 virus has accumulated many polymorphisms across its genome, especially 95 within the Spike gene (8). Shortly after the introduction of SARS-CoV-2 into the human 96 population, many early and dominant amino acid polymorphisms were associated with viral 97 entry fitness, such as D614G (9, 10). However, the pressure of the neutralising antibody 98 response might select for escape mutations in Spike that limit post-infectious immunity or 99 vaccine protection (11). One example is the S477N/D614G Spike variant which appeared in 100 Australia during July and August 2020 and was traced to a single event from Australian hotel 101 quarantine (12). The S477N/D614G Spike variant currently represents greater than 5% of 102 Spike variants worldwide, 15% in Europe, and 58% in Oceania (13). 103

Using the lessons learned from research of other viral pathogens and neuroimmunological 104 autoantibodies (14, 15), we have developed a suite of novel high-content assays that 105 sensitively assess antibody responses against the native oligomeric structure of Spike and its 106 emerging variants (16). To measure the neutralizing capacity, we have also developed a 107 Biosafety Level 2 surrogate Spike-driven virus-cell fusion assay that has been cross-validated 108 with a novel high content, machine-scored, Biosafety Level 3 authentic SARS-CoV-2 109 neutralization assay. 110 7 of Spike IgG levels was observed. No differences in Spike IgG and IgM levels were observed 135 between females and males, but higher IgG and IgM levels were associated with older age 136 (P<0.0001) (Fig. S1 ). Detection of convalescent positive serostatus was more sensitive when 137 Spike IgG were detected by live cell flow cytometry compared to Nucleocapsid IgG or Spike 138 IgG using commercial assays (Table 2) . whereas most LIFE donors exhibited decreased IgG over time (59%), where a decrease was 145 defined as >30% change from first collected sample (Fig. 1B) (14) . A two-phase decay in 146 those with decreasing responses characterized by an initial high rate of decay followed by 147 stabilization, and the breakpoint between the two phases was estimated at 85 days post-PCR 148 positivity (Fig. 1B) . The level at which Spike IgG stabilized was dependent on intial antibody 149 response. High Spike IgG levels decayed to mid-level reactivity and mid-low level reactivity 150 to low level (Fig. 1B) . In Spike IgM-positive patients, the majority had decreased IgM levels 151 over time (68% ADAPT; 84% LIFE), in which levels initially decreased and then stabilised 152 at lower levels, but did not serorevert up to 205 days (Fig. 1C) . Only five ADAPT (6%) and 153 fourteen LIFE (9%) individuals sero-reverted for Spike IgM at median 146 days post-PCR 154 positivity (Fig. 1C) . The breakpoint between the two phases of IgM decay was at 93 days 155 post-PCR positivity. 156

The polyantigenic breadth of Spike IgG-positive individuals against the virus was examined proteins ( Table 2) . 54% (45/83 ADAPT) and 57% (87/152 LIFE) individuals harboured IgG 159 targeting the SARS-CoV-2 Membrane protein, whereas 78% had antibody targeting the 160 Nucleocapsid protein (65/83 ADAPT, 118/152 LIFE) ( Fig. 1D and 1E ). Antibody titers 161 toward the Membrane protein remained stable over the period of observation in most 162 individuals (91%, 41/45 ADAPT; 95%, 83/87, LIFE), whereas responses toward the 163 Nucleocapsid protein differed between ADAPT and LIFE, and were reminiscent of the Spike 164

IgG response, i.e. mostly stable in ADAPT, and mostly decreased in LIFE over time (Fig. 1D  165 and 1E). Across both cohorts, reactivity to the Envelope protein was very limited with only 166 two ADAPT patients (2%) positive for Envelope IgG (Table 2) . Antibody responses to 167 SARS-CoV-2 were highly focused on Spike, followed by the Nucleocapsid and Membrane 168 proteins. Individuals with higher Spike IgG had also high levels of Nucleocapsid and 169

Membrane IgG (Fig. S1) . 170

The overall decay of SARS-CoV-2 antibodies between both cohorts behaved similarly for 171 Spike IgM, but not for Spike IgG, Membrane IgG, and Nucleocapsid IgG, with LIFE donors 172 exhibiting a higher proportion of decreased profiles (Fig. 1) . The first collected sample in 173 ADAPT started later post-PCR positivity, and the time duration between paired samples was 174 shorter than for LIFE samples, therefore some ADAPT patients may have been captured 175 during the 2 nd , more stable, phase ( Fig. 1 and Table 1 ). Furthermore, few ADAPT patients 176 underwent plasmapheresis, whereas all LIFE donors underwent plasmapheresis as part of 177 convalescent plasma donations (median 6 donations, IQR 3-9, max 14). However, donors 178 with more than 10 donations (n=30) had decay profiles similar to the whole cohort, in which 179 donors stabilized at mid-low level, and none of these highly recurrent donors became 180 seronegative (Fig. S2) . 181 182 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint

183 is maintained over time 184 The neutralization capacity of these individual responses was assessed on a Spike-driven 185 virus-cell fusion assay and a whole-virus neutralization assay (Fig. 1A) . Most sera were 186 capable of inhibiting virus-cell fusion (82%, 68/83 ADAPT; 68%, 104/152 LIFE) and 187 mediating viral neutralization (88%, 73/83 ADAPT; 94%, 143/152 LIFE) ( Fig. 2A , Table 2 ). 188

In both cohorts, the virus-cell fusion assay was more stringent than the SARS-CoV-2 189 neutralization assay as a proportion of individual sera with lower titers in the SARS-CoV-2 190 neutralization assay were negative in the virus-cell fusion assay (7%, 6/83 ADAPT; 27%, 191 41/152 LIFE), and most individuals had higher titers in the neutralization assay ( Fig. 2A) . To 192 understand the discrepancy between both viral assays, live SARS-CoV-2 viral particles were 193 enumerated and directly compared to Spike-pseudotyped lentiviral particles. Cell permeable 194 RNA-specific staining of live virions detected viral particles that were Nucleocapsid-positive 195 (Fig. 2B) . The particle to transduction ratios from the fusion assay were 1.03x10 5 , consistent 196 with the low specific infectivity of lentiviruses such as HIV-1(17). In contrast, the SARS-197

CoV-2 particle to infectivity ranged from 58 (HekAT14) to 578 (VeroE6), consistent with the 198 ratio reported for influenza virus (18). However, the absolute viral particle number was 74-199 fold higher in Spike-pseudotyped particle preparation (1.64x10 8 particles per ml) compared to 200 authentic SARS-CoV-2 (2.22x10 6 particles per ml). Thus, the specific infectivity of SARS-201 CoV-2 was higher than that of Spike-expressing lentiviral particles, which may account for 202 the higher sensitivity of the SARS-CoV-2-based neutralization assay. 203

Most ADAPT patients had stable virus-cell fusion inhibition (99%) and neutralization (89%) 204 titers over time ( Fig. 2C and 2D ). Most of LIFE donors had decreased virus-cell fusion 205 inhibition (82%) and neutralization (56%) capacity over time, and the majority exhibited a 206 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint single-phase decay in both assays ( Fig. 2C and 2D ). The greater number of samples per LIFE 207 donor enabled finer characterization of the decay profile in 34 donors in the virus-cell fusion 208 and 44 donors in the neutralization assay). Most donors had a single-phase decay, whilst a 209 two-phase decay was observed in those with >1:320 titers at first collection. These rapidly 210 dropped and then stabilized over time at 1:80 to 1:160 (28% and 25% of LIFE donors in the 211 virus-cell fusion and neutralization assays, respectively). Individuals with two-phase decay 212 had much higher starting titers than individuals with a single-phase decay (Fig. 2D ). In the 213 neutralization assay, LIFE donors with decreased profile had a similar median follow up as 214 the stable profile (~63 days and 56 days, respectively). In both cohorts, the neutralization and 215 fusion profiles were similar to the Spike IgG profiles, in which ADAPT had more stable 216 responses than LIFE. Indeed, Spike IgG and IgM titers were strongly correlated with virus-217 cell fusion inhibition and SARS-CoV-2 neutralization (Fig. 2E) . 218 instead, lost immunoreactivity to one antigen, either Nucleocapsid or Membrane. 229 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Patients had broader responses across the spectrum of severity in ADAPT (Fig. 3B) . ADAPT 230 and LIFE hospitalized patients with more severe symptoms were more likely to exhibit a 231 broader antibody response to SARS-CoV-2, i.e. polyreactive toward the three antigens ( A small subgroup of individuals were "high responders" characterized by high Spike IgG, 246

Spike IgM-positive, broad polyantigenic immunoreactivity (binding to Nucleocapsid, Spike, 247 and Membrane), virus-cell fusion inhibition (>1:160), and neutralization (>1:320). They 248 maintained this high response over time (n=14, 17% ADAPT, n=19, 12% LIFE). High 249 responders were more likely to be male, hospitalized, and were of older age (Fig. 4A) . 250

Further characterization was performed on a series of increasingly permissive cell lines, 251

VeroE6, HekAT14, HekAT10, and HekAT24 ( Fig. 4B and Fig. S3 ). Low, i.e. non-high 252 responders, and high responders sera neutralized live SARS-CoV-2 in VeroE6, HekAT14, 253 and HekAT10 cell lines, whereas limited neutralization was observed in the hyper-permissive 254 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint HekAT24 cell line (Fig. 4B ). Using the HekAT24 cell line, two elite responders were 255 identified in LIFE (Fig. 4C) , with high Spike IgG and IgM levels, and neutralization titers 30-256 to 4-fold greater than other individuals (Fig. 4D) . Interestingly, elite responders had the 257 highest detectable IgM levels, and early IgM decay coincided with a decrease in 258 neutralization titers, whereas Spike IgG remained stable overtime (Fig. 4E ). This association 259 between decreased IgM and neutralization titers was observed in ~10% of individuals in both 260 cohorts (data not shown). implicated in the Receptor Binding Domain (RBD) and S1 was assessed (Fig. 1A) . 268

Expression of all Spike variants was similar across each transfected cell line used in the flow 269 cytometry antibody assays (Fig. S4A ). Compared to the Wuhan-1 D614 variant, most patients 270 had similar binding and were able to recognise the Spike RBD variants G476F, V483A, and 271 V367S (Fig. 5A) . However, across both cohorts, there was an overall reduced binding to 272 D614G, a prominent non-RBD S1 variant present during the Australian first wave (Fig. 5A) . 273 65% of ADAPT and 91% of LIFE individuals, infected from the first world-wide wave, 274 generated antibodies that bound broadly to G476F, V483A, V367S, and D614G Spike, 275 whereas 35% of ADAPT and 9% of LIFE had more restricted Spike recognition; i.e. they 276 recognized G476F, V483A, V367S, but had a decreased binding to D641G (Fig. 5A) . 277 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Importantly, sera with reduced D614G IgG binding also had lower neutralization and virus-280 cell fusion inhibition compared to those who recognised D614G Spike ( were not distinguished by age and severity, but were more likely to be female (Fig. S5) . 292

Although D614G Spike remains a predominant variant globally (Fig. 5E ), in the second wave 293 of Australian infection between July to September, an isolate with additional polymorphisms, 294 primarily S477N, and in some cases an additional V1068F, was identified. These variants 295

were not detected during the first Australian wave (Fig. 5F ), which included the original 296 Wuhan-1 D614 or the D614G variant equally. To assess the antibody binding capacity 297 between original and emerging variants, patients infected by two Spike variants, 298 S477N/D614G and S477N/D614G/V1068F, were recruited during the second wave in 299 Australia (n=17, from the ADAPT cohort, Table 1 ). All ADAPT patients from the first and 300 second wave had detectable IgG against all Spike variants (Fig. S4B ). Compared to the 301 D614G variant, a strong decrease in immunoreactivity to S477N/D614G and 302 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint S477N/D614G/V1068F was observed in all ADAPT patients from the second wave, whereas 303 the third mutation within the Spike S2 domain V1068F did not have an additive effect (Fig.  304 5G). This decrease was also observed irrespective of the virus variant that had infected the 305 ADAPT patients (Fig. 5G ). Importantly ADAPT patients from the first wave, who had not 306 encountered the new variants, had reduced binding to S477N/D614G and 307 S477N/D614G/V1068F, suggesting a global decrease of immunoreactivity toward both new 308 variants (Fig. 5G) . The longevity of the immune response against SARS-CoV-2 is a fundamental yet currently 325 unresolved question. Like others, we observed a strong correlation between Spike IgG levels 326 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint and neutralization capacity (19, 20) . Although reports on neutralization prevalence and 327 average titers vary widely depending on sampling and detection assay strategies (21, 22), our 328 results expand on previous findings by comparing neutralization levels with antigen-specific 329 response over a longer follow-up period with more timepoints than most previous studies. 330

The decline in IgG titers and neutralization often stabilized at different levels later into 331 convalescence, addressing whether decreasing IgG levels eventually plateau. Especially in 332 LIFE whose samples were collected later post-infection and with a longer follow-up period 333 than ADAPT. Spike IgM levels decreased more rapidly than IgG, but were still detectable up high capacity commercial assays was significantly less sensitive compared to the flow 351 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Whilst the correlation of Spike IgG levels with viral neutralization was strong, high Spike 367 IgM levels were also associated with high viral neutralization in some, especially during the 368 early convalescent days. A lack of somatic mutations was observed in hundreds of cloned 369 neutralizing human antibodies from convalescent patients (26). In addition, many antibody 370 precursor sequences were observed in naïve B cells from pre-pandemic patient samples, 371 highlighting the importance of pre-existing germline antibody sequences in the neutralization 372 response. The lack of somatic mutations observed in IgG may be consistent with IgM being 373 potent in a neutralization response as both isotypes could have similar affinity binding sites 374

for Spike, but with multiple binding sites per molecule on IgM, the avidity for Spike would 375 be higher. 376 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint Full virus neutralization and prevention of virus-cell fusion were associated. Whilst many 377 assays aim to assess neutralization surrogates outside of level 3 biosafety laboratories, key 378 differences were observed between Spike-driven virus-cell fusion and the authentic SARS-379

CoV-2 assay. In our study, the particle to transduction ratio in the virus-cell fusion assay was 380 much higher than the SARS-CoV-2 neutralization assay. This is consistent with the 381 respective infectivity of HIV-1 compared to respiratory viruses such as SARS, non-SARS 382 coronaviruses, and influenza (17, 18). The virus-cell fusion assay involves a single round of 383 infection, whereas the full virus in the neutralization assay is replication-competent and 384 undergoes multiple rounds of replication over a three day culture. Therefore, the spread of the 385 virus must be considered alongside the capacity of antibodies to inhibit the initial single 386 particle entry and blocking of the virus spread between cells. Although the pseudotyping 387 fusion assay had lower sensitivity, most individuals across both cohorts had titers in this 388 assay with potency ranking similar to full virus neutralization. 389

Transfusion of convalescent COVID-19 plasma has been proposed as a therapy, with >70 390 ongoing randomized controlled trials. The few clinical trials to date have supported an 391 acceptable safety profile, but evidence regarding efficacy is mixed (27). Most unsuccessful 392 trials included donors with unknown neutralizing status or FDA-classified low titers, whereas 393 successful trials either used high-titer or convalescent COVID-19 plasma delivered within 394 three days of hospitalization (28). Indeed, utility of convalescent plasma could be improved 395 by donations during early disease stages and by selecting donors with high neutralization 396 antibody titers (29). Our findings that the immunological response to SARS-CoV-2 is widely 397 heterogeneous, with large variations in SARS-CoV-2 antibodies and neutralization, 398 polyantigenic immunoreactivity, and longitudinal responses complement these assertions. To 399 take into account the first phase of decay observed during early convalescence, we propose 400 an optimal window for plasmapheresis, up to 100 days post-diagnosis. Furthermore, the 401 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint occurrence of a small group of individuals, termed "high and elite responders" with highly 402 neutralising, broad, and sustained SARS-CoV-2 antibody responses over time, may be due to 403 the rapid and lasting generation of memory B cells (30). These patients were likely to be 404 hospitalized older males. Alongside appropriate serology screening programs, the targeted 405 recruitment for plasma donations could help to identify optimal convalescent resources 406 available within affected communities. them. This could be a major concern for vaccine candidate design, especially given the 426 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our study has important translatable implications to understand the natural history of 444 COVID-19, and post-infection and vaccination-induced immunity. We have highlighted that 445 molecular epidemiology and sero-surveillance will both be required to detect emerging 446 polymorphisms. Furthermore, sensitive monitoring of antibody binding and neutralization 447 capacity will be paramount in vaccine design strategy and convalescent plasma therapy, and 448 in seroprevalence studies, and this would require involvement of more rapidly adaptive 449 methodologies to characterize the magnitude of the neutralization antibody responses against 450 emerging variants. 451 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint

This study investigated two cohorts of RT-PCR-confirmed convalescent individuals recruited 455 from February to October 2020 in Australia (Table 1 

474 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

496 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint

The hACE2 ORF (Addgene# 1786) was cloned into a 3rd generation lentiviral expression 497 vector and clonal stable ACE2-expressing Hek293T cells were generated by lentiviral 498 transductions (36). Lentiviral particles pseudotyped with SARS-CoV-2 Spike envelope were 499 produced by co-transfecting Hek293T cells with a GFP encoding lentiviral plasmid HRSIN-500 CSGW (37), psPAX2, and plasmid expressing C-terminal truncated Spike (pCG1-SARS-2-S 501 Delta18) (38) including D614 or D614G (36). Neutralization activity of sera was measured 502 using a single round infection of ACE2-HEK293T with Spike-pseudotyped lentiviral 503 particles. Virus particles were incubated with serially diluted donor sera for 1 hour at 37°C. 504

Virus-serum mix was then added onto ACE2-HEK293T cells (2.5x10 3 /well) in a 384-well 505 plate. Following spinoculation at 1200g for 1 hour at 18°C, the cells were moved to 37°C for 506 72 hours. Entry of Spike particles was imaged by GFP-positive cells (InCell Analyzer) 507 followed by enumeration with InCarta software (Cytiva, USA). Neutralization was measured 508 by reduction in GFP expression relative to control group infected with the virus particles 509 without any serum treatment. 510

The virus entry pathway in VeroE6, used in live virus neutralization assays, is primarily 511 endosomal (39). In contrast, cells derived from nasopharyngeal tissues, express ACE2 in 512 addition to the surface serine protease TMPRSS2 which drives virus-cell membrane fusion 513 and can signficantly enhance viral entry (38). To address viral neutralization in the presence 514 of ACE2 and TMPRSS2, a portfolio of Hek293T expressing clonal cell lines with ACE2 and 515 TMPRSS2 (HekAT) was generated. The coexpression of ACE2 and TMPRSS2 led to a series 516 of increasingly permissive cell lines that were readily susceptible to SARS-CoV-2 cytopathic 517 effects, VeroE6, HekAT14, HekAT10, HekAT24 (Fig. S3) . 518

High content fluorescdent live SARS-CoV-2 neutralization assay 519 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint Sera were serially diluted and mixed in duplicate with an equal volume of virus solution at 520 1.5x10 3 TCID50/mL. After 1 hour of virus-serum coincubation at 37°C, 40μL were added to 521 equal volume of freshly-trypsinized VeroE6 cells, and three clonal HekAT cells in 384-well 522 plates (5x10 3 /well) selected on SARS-CoV-2 permissiveness. After 72h, cells were stained 523 with NucBlue (Invitrogen, USA) and the entire well was imaged with InCell Analyzer. 524

Nuclei counts, proxy for resulting cytopathic effect, were compared between convalescent 525 sera, mock controls (defined as 100% neutralisation), and infected controls (defined as 0% Sensoplates (Sigma Aldrich, USA) through spinoculation at 1200g for 1 hour at 18°C. 536

Particles were either imaged live or immune-fluorescently counter-stained using a rabbit 537 polyclonal SARS-CoV-2 Nucleocapsid antibody, followed by Alexa647-conjugated goat 538 anti-rabbit IgG (Novus Biologicals, USA). Viral particles were then imaged and quantified as 539 previously described (40). Particle to infectivity ratios were determined by dividing the total 540 particle count per ml with the calculated TCID50/ml. Particle to GFP transduction ratios were 541 used for lentiviruses. 542 543 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint

Clinical respiratory samples were sequenced using an existing amplicon-based Illumina 545 sequencing approach. The raw sequence data were subjected to an in-house quality control 546 procedure before further analysis as reported in (41) All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. IgM, Membrane IgG, and Nucleocapsid IgG levels. High virus-cell fusion inhibition and 708 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. n/a n/a n/a n/a n/a n/a n/a n/a preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.19.20248567 doi: medRxiv preprint

Humoral Immune Response to SARS-CoV-2 in Iceland

Persistence of serum and saliva antibody responses to SARS-CoV-2 566 spike antigens in COVID-19 patients

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with 568 Mild Covid-19

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, 570 population-based seroepidemiological study

Isolation of potent SARS-CoV-2 neutralizing antibodies and 572 protection from disease in a small animal model

Camostat mesylate inhibits SARS-CoV-2 activation by 574 TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Robust neutralizing antibodies to SARS-CoV-2 infection persist 577 for months

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and 579 Antigenicity

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo 581 and transmission in vivo

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G 583 Increases Infectivity of the COVID-19 Virus

Landscape analysis of escape variants identifies SARS-CoV-2 spike 585 mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv

Tracking SARS-CoV-2 mutations by locations and dates of interest. bioRxiv

Emergence and spread of a SARS-CoV-2 variant through 590 Europe in the summer of 2020. medRxiv

Characterization of the human myelin oligodendrocyte glycoprotein 592 antibody response in demyelination

A clinical approach to diagnosis of autoimmune encephalitis

Broadly Neutralizing Antibodies to HIV and Their Role 596 in Vaccine Design

Molecular determinants of the ratio of inert to infectious virus particles

Transport of incoming influenza virus nucleocapsids into the 600 nucleus

Persistence and decay of human antibody responses to the receptor 602 binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Sex, age, and hospitalization drive antibody responses in a COVID-605 19 convalescent plasma donor population

Convergent antibody responses to SARS-CoV-2 in convalescent 607 individuals

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 609 Inpatients and Convalescent Patients

Evolution of immunity to SARS-CoV-2. medRxiv

Viral epitope profiling of COVID-19 patients reveals cross-reactivity 615 and correlates of severity

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-617

Neutralizing Antibodies from COVID-19 Patients

Convalescent plasma or hyperimmune immunoglobulin for people 619 with COVID-19: a living systematic review

Clinical efficacy of convalescent plasma for treatment of 622 COVID-19 infections: Results of a multicenter clinical study

Significantly Decreased Mortality in a Large Cohort of Coronavirus 625 Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma 626 Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 627 (SARS-CoV-2) Spike Protein IgG

Long-Term Persistence of Neutralizing Memory B Cells in 629 Sars-Cov-2. SSRN

Ebola Virus Glycoprotein with Increased Infectivity Dominated the

Structural and Functional Analysis of the D614G SARS-CoV-633

Influenza vaccines: challenges and solutions

Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-637

CoV-2 Spike. bioRxiv

Quantification of the Impact of the HIV-1-Glycan Shield on Antibody 639 Elicitation

Mobilization of HIV spread by diaphanous 2 dependent filopodia 641 in infected dendritic cells

Efficient lentiviral transduction of Herpesvirus saimiri 643 immortalized T cells as a model for gene therapy in primary immunodeficiencies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and 646

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-648 CoV-2 Infection

Resolution of de 650 novo HIV production and trafficking in immature dendritic cells

Revealing COVID-19 transmission in Australia by SARS-CoV-2 653 genome sequencing and agent-based modeling

We thank all the patients and donors who participated in this study. We ** *** **